Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2022-06-07 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于注销公司2018年（第二期）股票期权激励计划部分预留授予股票期权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the cancellation of part of its 2018 (second phase) stock option incentive plan. It details board and supervisory meetings, adjustments to stock option grants, and legal opinions related to the stock option plan. The content focuses on changes to stock option incentives, including cancellations and adjustments, rather than financial results, earnings, or annual reports. It is not a full financial report or earnings release but a corporate announcement about stock option plan changes. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as stock option plans.
2022-06-07 Chinese
关于独立董事任期届满离任的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of an independent director due to term expiration and compliance with regulatory requirements. It details the director's tenure, resignation process, and the company's plan to fill the vacancy. There is no financial data, audit information, or report content. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2022-06-07 Chinese
关于董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director, YI SHI, from the board and related committees. It includes details about the director's term, reasons for resignation, and confirms that the resignation will not affect the board's operation. There is no financial data, report, or presentation content. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2022-06-07 Chinese
2018年（第二期）股票期权激励计划预留授予股票期权第二个行权期可行权激励对象名单
Share Issue/Capital Change Classification · 95% confidence The document is titled as a list of stock option incentive plan reserved stock options for the second exercise period in 2018, specifically naming directors, senior management, and core technical/business personnel eligible for exercising stock options. It contains detailed tables listing individuals and their stock option quantities. The content focuses on stock option awards and related personnel, which is related to share-based compensation and capital changes. There is no indication of a full financial report, earnings release, or regulatory certification. The document is not a report publication announcement or a brief summary but a detailed list of stock option allocations. This fits best under the category of Share Issue/Capital Change (SHA), as it relates to stock option grants and changes in capital structure through equity incentives.
2022-06-07 Chinese
关于注销公司2018年（第一期）股票期权激励计划第三个行权期满未行权股票期权的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the cancellation of unexercised stock options under a 2018 stock option incentive plan. It details the background, approval process, and legal compliance related to the cancellation of these stock options. The content focuses on corporate governance and management decisions about stock option plans, rather than financial results, audit opinions, or shareholder meeting materials. It is not a full annual or interim report, nor is it a call transcript or earnings release. It is also not a proxy solicitation or voting results announcement. The document is a regulatory announcement about management decisions on stock options, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories and is a formal disclosure to the market.
2022-06-07 Chinese
独立董事关于第三届董事会第三十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on various matters related to the company's stock option incentive plans, including adjustments to exercise prices, cancellation of certain stock options, and confirmation of exercise conditions. It references compliance with regulatory guidelines and company rules, and it is dated June 6, 2022. The content is focused on governance and compliance opinions rather than financial results or report publication. The document length is 2426 characters, which is relatively short and does not contain financial statements or detailed financial data. It is not an announcement of a report publication but an official opinion related to board meeting matters. This fits best under Board/Management Information (MANG), as it relates to board-level decisions and opinions on stock option plans and governance matters.
2022-06-07 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.